期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

不同常规剂量他汀预防对比剂肾病的临床研究 被引量：6

暂未订购
导出
摘要 目的:比较冠状动脉介入诊疗前不同常规剂量他汀预防对比剂肾病(CIN)的疗效。方法:入选我院择期行冠状动脉介入诊疗手术患者127例,分为对照组、A组(阿托伐他汀10mg)、B组(阿托伐他汀20mg),药物连续服用3d以上。比较术后3组患者24、48、72h血肌酐(Scr)变化和CIN发生率。结果:(1)术后CIN的总发生率为11.02%,对照组6.67%(1例),A组13.60%(3例),B组11.10%(10例),组间比较差异无统计学意义(P>0.05);(2)术后3组患者Scr水平在48、72h升高幅度组间比较差异无统计学意义(P>0.05)。结论:冠状动脉介入诊疗术前不同常规剂量他汀预防CIN的作用无差异。
作者 吴云涛 邢爱君 关凤焕 黄宇玲 郑晓明
机构地区 河北联合大学附属开滦总医院心内科 河北联合大学附属医院心内科
出处 《实用医学杂志》 CAS 北大核心 2013年第9期1471-1472,共2页 The Journal of Practical Medicine
关键词 肾病 阿托伐他汀 冠状动脉介入治疗
分类号 R692.9 [医药卫生—泌尿科学]
  • 相关文献

参考文献8

  • 1Pemson P B, Tepel M. Contrast medium-induced nephropathy: the pathophysiology (Review) [ J ]. Kidney Int Suppl, 2006,3 (100) :S8-10.
  • 2Thomsen H S. Guidelines for contrast media from the European Society of Urogenital Radiology [J]. Am J Roentgenol, 2003, 181 (6) : 1463-1471.
  • 3Mehran R, Aymong E D, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after pereutaneous coronary intervention: development and initial validation [J]. J Am Coil Cardiol, 2004,44(7) : 1393-1399.
  • 4刘俊,张怀勤,黄伟剑,计光,蔡雪黎.对比剂肾病与肾动脉硬化的相关性研究[J].实用医学杂志,2010,26(24):4510-4512. 被引量：1
  • 5马玉良,王伟民,刘健,卢明瑜,李琪,刘传芬.超敏C反应蛋白与对比剂肾病关系的研究[J].中国循环杂志,2009,24(6):418-420. 被引量：23
  • 6Chello M, Goffredo, Patti G, et al. Effects of atorvastatin on arterial endothelial function in coronary bypass surgery [J]. Eur J Cardiothorac Surg, 2005, 28(6): 805-810.
  • 7廖方清.阿托伐他汀对急性心肌梗死患者MMP-2、MMP-9的影响[J].现代医院,2011,11(6):49-50. 被引量：14
  • 8Bonnet J, McPherson R, Tedgui A, et al. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C- reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study [J]. Clin Thor, 2008,30(12):2298-2313.

二级参考文献33

  • 1殷忠,李兰荪,张荣庆,刘安恒,栾荣华,王海昌.冠心病患者外周血MMP-9、CRP的变化及其临床意义[J].中国康复医学杂志,2006,21(4):318-321. 被引量：7
  • 2夏勇,李先进,杨煜,李东野.氟伐他汀对急性心肌梗死患者循环单核细胞基质金属蛋白酶9和组织因子表达的影响[J].中国动脉硬化杂志,2006,14(3):237-239. 被引量：2
  • 3McCullough PA. Contrast-inducedacute kidney injury. J Am Coll Cardiol,2008,51 : 1419-1428.
  • 4Jabara R, Gadesam RR, Pendyala LK, et al. Impact of the definition utilized on the rate of contrast-induced nephropathy in pereutaneous coronary intervention. The American Journal of Cardiology,2009,103 : 1657-1662.
  • 5Goldenberg I, Matetzky S. Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. Can Med Assoc J, 2005,172 : 1461-1471.
  • 6Tumlin J, Stacul F, Adam A, et al. Pathophysiology of contrast-induced nephropathy, Am J Cardiol,2006,98 (suppl) : 14-20.
  • 7Marenzi G, Assanelli E, Marana I, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med, 2006, 354:2773-2782.
  • 8Briguori C, Aimldi F, D'Andrea D, et al. Renal insufficiency following contrast media administration trial (REMEDIAL) : a randomized comparison of 3 preventive strategies. Circulation ,2007,115 : 1211-1217.
  • 9Toprak O, Cirit M. Risk factors for contrast-induced nephropathy. Kidney Blood Press Res,2006,29:84-93.
  • 10Bartholomew BA, Harjai K J, Dukkipati S, et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol,2004,93 : 1515-1519.

共引文献35

同被引文献86

  • 1赵凯,杨万松,陈树涛,谭强,丛洪良,张成,李广平.C反应蛋白与原发性高血压及其危险因素的关系[J].天津医药,2007,35(4):253-255. 被引量：2
  • 2NAVARRO J F, MORA C, MACA M, et al. , Inflammatory param- eters are independently associated with urinary albumin in type 2 di- abetes mellitus[J]. Am J Kidney Dis, 2003,42( 1 ) : 53 -61.
  • 3ARIK H O,YALCIN A D, GUMUSLU S, et al. Association of cir- culating strail and high - sensitivity CRP with type 2 diabetic ne- phropathy and foot ulcers [ J ]. Med Sci Monit, 2013,19 : 712 - 715.
  • 4ABRAHAMIAN H, ENDLER G, EXNER M,et al. Association of low- grade inflammation with nephropathy in type 2 diabetic pa- tients: role of elevated CRP - levels and 2 different gene - poly- morphisms of proinflammatory cytokines[J]. Exp Clin Endocrinol Diabetes, 2007,115( 1 ) : 38 -41.
  • 5RAKITIANSKAIA I A, RIABOV S l, DUBROVA A G, et al. The role of IL - 6 in the development of morphological changes in renal tissue in elderly patients with type 2 diabetes complicated by dia- betic nephropathy[J]. Adv Gerontol, 2012,25(4): 632-637.
  • 6ARABABADI M K, REZA MIRZAEI M, ALI SAJADI S M, et al. Interleukin (IL) - 10 gene polymorphisms are associated with type 2 diabetes with and without nephropathy: a study of patients from the southeast region of Iran [ J ]. Inflammation, 2012,35 (3) : 797 - 802.
  • 7ATHYROS V G, MIKHAILIDIS D P, PAPAGEORGIOU A A, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analy- sis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study[J]. J Clin Pathol, 2004,57(7) : 728 -734.
  • 8COLHOUN H M, BETTERIDGE D J, DURRINGTON P N,et al. Effects of atorvastatin on kidney outcomes and cardiovascular dis- ease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study ( CARDS ) [ J ]. Am J Kidney Dis, 2009,54(5) : 810 -819.
  • 9陈丽云,王爱民,陈福顺,刘建华.糖尿病患者慢性并发症及其影响因素研究[J].江苏预防医学,2007,18(4):1-3. 被引量：4
  • 10Briguori C,Airoldi F,Morici N,et al. New pharmaco- logical protocols to prevent or reduce contrast media nephropathy[J]. Minerva Cardioangiol, 2005,53 ( 1 ) : 49- 58.

引证文献6

二级引证文献52

实用医学杂志
2013年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部